Niek B Achten1, Pingsheng Wu2, Louis Bont1, Maarten O Blanken1, Tebeb Gebretsadik3, James D Chappell4, Li Wang3, Chang Yu3, Emma K Larkin2, Kecia N Carroll5, Larry J Anderson6, Martin L Moore6, Chantel D Sloan7, Tina V Hartert2. 1. Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands. 2. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine. 3. Department of Biostatistics. 4. Department of Pathology, Microbiology, and Immunology, and. 5. Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee. 6. Department of Pediatrics, Emory University, Atlanta, Georgia; and. 7. Department of Health Science, College of Life Sciences, Brigham Young University, Provo, Utah.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) and human rhinovirus (HRV) are the most common viruses associated with acute respiratory tract infections in infancy. Viral interference is important in understanding respiratory viral circulation and the impact of vaccines. METHODS: To study viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in 2 prospective birth cohort studies (the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children's Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), using adjusted multivariable regression analyses. RESULTS: Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively. The odds of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds ratios of 0.30 (95% confidence interval [CI], .22-.40 in the INSPIRE study, 0.18 (95% CI, .11-.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16-.72) in the MAKI trial. HRV infection was significantly more common among infants administered RSV immunoprophylaxis, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65-2.39). CONCLUSIONS: A negative association of RSV on HRV codetection was consistently observed across populations, seasons, disease severity, and geographical regions. Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV infection.
BACKGROUND: Respiratory syncytial virus (RSV) and human rhinovirus (HRV) are the most common viruses associated with acute respiratory tract infections in infancy. Viral interference is important in understanding respiratory viral circulation and the impact of vaccines. METHODS: To study viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in 2 prospective birth cohort studies (the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children's Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), using adjusted multivariable regression analyses. RESULTS: Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively. The odds of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds ratios of 0.30 (95% confidence interval [CI], .22-.40 in the INSPIRE study, 0.18 (95% CI, .11-.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16-.72) in the MAKI trial. HRV infection was significantly more common among infants administered RSV immunoprophylaxis, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65-2.39). CONCLUSIONS: A negative association of RSV on HRV codetection was consistently observed across populations, seasons, disease severity, and geographical regions. Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV infection.
Authors: K Loens; A M van Loon; F Coenjaerts; Y van Aarle; H Goossens; P Wallace; E J C Claas; M Ieven Journal: J Clin Microbiol Date: 2011-12-14 Impact factor: 5.948
Authors: Benjamin J Cowling; Vicky J Fang; Hiroshi Nishiura; Kwok-Hung Chan; Sophia Ng; Dennis K M Ip; Susan S Chiu; Gabriel M Leung; J S Malik Peiris Journal: Clin Infect Dis Date: 2012-03-15 Impact factor: 9.079
Authors: Sylvie Pillet; Marina Lardeux; Julia Dina; Florence Grattard; Paul Verhoeven; Jérôme Le Goff; Astrid Vabret; Bruno Pozzetto Journal: PLoS One Date: 2013-08-23 Impact factor: 3.240
Authors: Fahad Gulraiz; Carla Bellinghausen; Mieke A Dentener; Niki L Reynaert; Giel R Gaajetaan; Erik V Beuken; Gernot G Rohde; Cathrien A Bruggeman; Frank R Stassen Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240
Authors: Leigh M Howard; Yuhan Liu; Yuwei Zhu; Dandan Liu; John V Willams; Ana I Gil; Marie R Griffin; Kathryn M Edwards; Claudio F Lanata; Carlos G Grijalva Journal: J Infect Dis Date: 2022-01-05 Impact factor: 7.759
Authors: James T Van Leuven; Andres J Gonzalez; Emmanuel C Ijezie; Alexander Q Wixom; John L Clary; Maricris N Naranjo; Benjamin J Ridenhour; Craig R Miller; Tanya A Miura Journal: mSphere Date: 2021-06-23 Impact factor: 4.389